Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Icahn And Eastbourne Win Some, Lose Some In Amylin Match

Executive Summary

Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course

You may also be interested in...



As Rumors About A Potential Acquisition Fly, Elan Names Two Dissidents To Its Board

Avoiding a proxy fight, the Irish firm placed two hostile members on its board, likely spelling trouble for CEO Martin.

But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”

After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board

But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”

After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board

Related Content

Topics

UsernamePublicRestriction

Register

PS051121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel